Chai Discovery closed a $130 million Series B round at a $1.3 billion valuation, extending the rapid funding trajectory of the AI‑driven biotech founded in 2024. The financing was led by growth investors and positions the company to scale its AI platform for drug discovery and molecule optimization. Chai’s raise underscores investor appetite for platform‑first AI biotechs that promise to accelerate lead identification and reduce preclinical timelines. The company will use proceeds to expand computational capabilities, run larger discovery campaigns, and advance candidate generation toward preclinical development.